NCT03590626View on ClinicalTrials.gov

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

January 14, 2020

Study Completion Date

February 18, 2020

Conditions
Non Alcoholic Fatty Liver DiseaseType2 Diabetes Mellitus
Interventions
DRUG

Dulaglutide

0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks

Trial Locations (1)

122001

Division Of Endocrinology & Diabetes, Medanta The Medicity, Gurgaon

All Listed Sponsors
lead

Medanta, The Medicity, India

OTHER

NCT03590626 - Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter